Education
About Us
Working with TipRanks
Follow Us
Verastem (VSTM)
NASDAQ:VSTM
VSTM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.10 - $13.52
Previous CloseN/A
Volume547.29K
Average Volume (3M)750.12K
Market Cap
$338.27M
Enterprise Value$205.26M
Total Cash (Recent Filing)$91.53M
Total Debt (Recent Filing)$125.98M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 08, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.49
Shares Outstanding51,486,706
10 Day Avg. Volume722,792
30 Day Avg. Volume750,122
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)29.60
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.31K
Enterprise Value/Ebitda-1.99
Forecast
1Y Price Target
$12.50Price Target Upside95.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Verastem News
PremiumCompany Announcements
Verastem Unveils Strategic Plans in New Presentation
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRaising revenue expectations for LGSOC to a risk-adjusted $211M per year, up from a previous estimate of $141M.
Regulatory MilestoneThe FDA acceptance of the new drug application for the combination of avutometinib and defactinib for low-grade serous ovarian cancer is seen as a key milestone for Verastem Inc.
Strategic PartnershipsPartnerships and licensing agreements, like the one with IQVIA, support the initial product launch and enhance the company's growth potential.
Bears Say
Market ReactionVSTM shares are down approximately 20% due to the news that the company will initially seek approval only in KRAS-mutant patients, not KRAS-wild-type patients.
Regulatory ChallengesThe company will initially seek approval only in KRAS-mutant patients, which limits the immediate market scope for the new treatment.
---
Ownership Overview
1.40% Insiders
7.35% Mutual Funds
42.49% Other Institutional Investors
39.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VSTM FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest stock price was $2.10 and its highest was $13.52 in the past 12 months.
What is Verastem’s market cap?
Verastem’s market cap is $338.27M.
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is May 08, 2025 which is in 41 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on Mar 20, 2025. The company reported -$1.33 earnings per share for the quarter, missing the consensus estimate of -$0.829 by -$0.501.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -0.64.
How many shares outstanding does Verastem have?
Verastem has 51,486,706 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$1.33 in its last earnings report, missing expectations of -$0.829. Following the earnings report the stock price went down -2.493%.
Which hedge fund is a major shareholder of Verastem?
Currently, no hedge funds are holding shares in VSTM
---
Verastem Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.50 (95.31% Upside)
$12.50 (95.31% Upside)
Blogger Sentiment
Bullish
VSTM Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 723.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $58.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 7.3%
Last 30 Days ▼ 7.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.77%
12-Months-Change
Fundamentals
Return on Equity
-526.33%
Trailing 12-Months
Asset Growth
-32.18%
Trailing 12-Months
Company Description
Verastem
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
---
VSTM Stock 12 Month Forecast
Average Price Target
$12.50
▲(95.31% Upside)
Technical Analysis
Best Analysts Covering VSTM
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
+20.72%
reiterated a buy rating 7 days ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +20.72% per trade.
---